For investors willing to take a 10-year view, a handful of ASX growth shares stand out right now. When it comes to long-term investing, the real winners are often businesses with durable competitive advantages and exposure to powerful structural trends.
Here are three ASX growth shares, down between 15% and nearly 40% this year, that could be worth buying and holding through to 2036.
ResMed Inc (ASX: RMD)
First up is ResMed, a global leader in treating sleep apnoea and respiratory conditions. The ASX growth share develops devices, masks, and digital health platforms used in both clinical and home settings, positioning it squarely within long-term trends like ageing populations, rising sleep health awareness, and the shift toward home-based care.
ResMed’s strength lies in its ecosystem. It operates across devices, consumables, software, and data platforms, creating recurring revenue and strong customer retention. Recent results highlight that momentum, with quarterly revenue rising 11% to US$1.4 billion and earnings per share jumping 21% to US$2.86.
The opportunity is also massive. More than 1 billion people globally are estimated to have sleep apnoea, yet diagnosis and treatment rates remain low. That gives ResMed a long runway for growth without needing to create new markets.
Morgans Financial has a $41.72 price target on the ASX growth share, implying solid upside from current levels.
Life360 Inc (ASX: 360)
Next is Life360, a more volatile but potentially high-reward growth play. The ASX growth share has fallen sharply, down around 38% in 2026, even as the business continues to expand.
Life360 operates a location-based app focused on family safety and connectivity. Crucially, it is shifting toward a subscription-driven model, which should improve revenue predictability over time.
Despite softer sentiment, recent performance has been strong. In its latest quarterly update, revenue increased 26% year-on-year to US$146 million, while EBITDA surged 53% to US$32.4 million.
The broader tech reset, particularly around artificial intelligence, has weighed on investor sentiment toward smaller platform businesses. But Life360 still sits within a growing digital ecosystem and continues to scale. Morgan Stanley has reiterated its buy rating with a $30 price target, pointing to meaningful upside.
HUB24 Ltd (ASX: HUB)
Finally, HUB24 is a standout in the local fintech space. This $7 billion ASX growth share continues to deliver strong operational momentum as advisers increasingly adopt its platform.
In its latest quarterly update, HUB24 reported net inflows of $4 billion, with total funds under administration reaching $151.7 billion, up 22% year-on-year. That reflects both strong inflows and continued platform adoption.
The structural story is compelling. More than 5,200 advisers now use HUB24, and the trend toward platform monogamy â where advisers consolidate onto a single provider â is working in its favour. This is a business gaining market share in a growing industry.
Jarden has a buy rating on HUB24 with a $115.30 price target, suggesting solid upside potential.
Foolish Takeaway
The bottom line is that all three ASX growth shares are exposed to long-term growth drivers and are building scalable, high-quality businesses.
While short-term volatility is inevitable, investors focused on the next decade rather than the next quarter may find these ASX growth shares well worth holding.
The post 3 of the best Aussie ASX growth shares to buy and hold until 2036 appeared first on The Motley Fool Australia.
Should you invest $1,000 in ResMed right now?
Before you buy ResMed shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and ResMed wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- 5 things to watch on the ASX 200 on Thursday
- 3 ASX 200 shares on my May watchlist
- 3 reasons to buy this $42 billion ASX healthcare share
- Forget gold! Start hunting fallen ASX 200 shares to buy for an earlier retirement
- 3 high-quality ASX growth shares for smart investors to buy and hold for 10 years
Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Hub24, Life360, and ResMed. The Motley Fool Australia has positions in and has recommended Life360 and ResMed. The Motley Fool Australia has recommended Hub24. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.